The August issue of The Lancet Microbe is now online:
https://thelancet.com/journals/lanmic/issue/current
The journal is #OpenAccess 🔓, so you are free to explore all of its content, but these hashtags offer a flavour:
#COVID19 #SARSCoV2 #AMR #Paenibacillus #hydrocephalus #BNT162b2 #HCV #hepatitis #tachykinins #tuberculosis #TB #OA
#openaccess #COVID19 #SarsCoV2 #AMR #paenibacillus #hydrocephalus #BNT162b2 #HCV #hepatitis #tachykinins #Tuberculosis #tb #oa
In those without a #COVID19 history, similar antibody production was reached 45 days after vaccination. Although total antibodies decline considerably in the first 2 months, the neutralizing antibodies & their inhibitory capacity (>96%) persist up to 6 months after the first dose of #BNT162b2 @Vaccines_MDPI
📌 https://www.mdpi.com/2076-393X/11/6/1127
📌 https://www.mdpi.com/journal/vaccines/special_issues/vaccines_antibody
BNT162b2 vaccine protection against omicron and effect of previous infection variant and vaccination sequence among children and adolescents in Singapore: a population-based cohort study - The Lancet Child & Adolescent Health https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(23)00101-3/fulltext “In previously infected children and adolescents, #BNT162b2 #vaccination provided additional protection against omicron #BA4 or #BA5 and #XBB #variants compared with those who remained #unvaccinated.
#BNT162b2 #vaccination #BA4 #BA5 #xbb #variants #unvaccinated
https://www.news-medical.net/news/20230303/Does-the-incidence-of-reported-myocarditis-or-pericarditis-after-BNT162b2-vaccination-vary-by-age-sex-and-inter-dose-interval-among-adolescents-aged-12-to-17.aspx “During the study period, 1.65 million doses of #BNT162b2 were administered in Canada. However, only 77 #myocarditis/pericarditis events among 12 to 17-year-olds met the inclusion criteria.
#myocarditis or #pericarditis post-BNT162b2 vaccination was rare, i.e., <0.01% in participating adolescents; however, slightly greater in the 16 to 17-year age group than the 12 to 15-year age group. Thankfully, emergency departments (EDs) handled nearly all these incidents (96.1%)”
#BNT162b2 #myocarditis #pericarditis
#Effectiveness of #BNT162b2 #Vaccine against #Omicron #Variant Infection among #Children 5–11 Years of Age, Israel https://wwwnc.cdc.gov/eid/article/29/4/22-1285_article
#effectiveness #BNT162b2 #vaccine #omicron #variant #children
#IDMastodon #publichealth @thelancetinfdis #Clinicalreview Risk of and #COVID19vaccines effectiveness against infection with the #omicronvariant of #SARSCoV2 in adolescents vaccinated with 2 doses of 30 μg BNT162b2 vs two doses of 10 μg #BNT162b2
📌https://www.thelancet.com/action/showFullTableHTML?isHtml=true&tableId=tbl1&pii=S1473-3099%2823%2900005-1
📌 https://www.thelancet.com/journals/laninf/home
📌 https://www.thelancet.com/issue/S1473-3099(23)X0002-4
#IDMastodon #publichealth #clinicalreview #COVID19vaccines #omicronvariant #SarsCoV2 #BNT162b2
[Correspondence] #BNT162b2 #antigen dose and #SARS-CoV-2 #omicron infection in #adolescents https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00005-1/fulltext?rss=yes
#BNT162b2 #antigen #sars #omicron #adolescents
#BNT162b2 #effectiveness against #Delta and #Omicron #variants of #SARS-CoV-2 in #adolescents aged 12-17 years, by dosing interval and duration https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiad006/6988115?rss=1
#BNT162b2 #effectiveness #delta #omicron #variants #sars #adolescents
Immunogenicity and safety in healthy adults of full dose versus half doses of #COVID19 #vaccine (#ChAdOx1-S or #BNT162b2) or full-dose #CoronaVac administered as a #booster dose after priming with CoronaVac: a randomised, observer-masked, controlled trial in #Indonesia https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00800-3/fulltext?rss=yes
#COVID19 #vaccine #chadox1 #BNT162b2 #coronavac #booster #indonesia
RT @LancetMicrobe@twitter.com
New in @TheLancetInfDis@twitter.com> Effectiveness of #BNT162b2 and #CoronaVac #COVID19 vaccination against asymptomatic and symptomatic infection of #SARSCoV2 omicron BA.2 in #HongKong: a prospective cohort study https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00732-0/fulltext#.Y5henhMbolI.twitter
🐦🔗: https://twitter.com/LancetMicrobe/status/1602623218828853248
#BNT162b2 #CoronaVac #COVID19 #SarsCoV2 #hongkong
#Effectiveness of #BNT162b2 and #CoronaVac #COVID19 #vaccination against asymptomatic and symptomatic #infection of #SARS-CoV-2 #omicron #BA2 in #HK: a prospective cohort study, https://doi.org/10.1016/S1473-3099(22)00732-0
#effectiveness #BNT162b2 #coronavac #COVID19 #vaccination #infection #sars #omicron #ba2 #hk
#Comparison of five Anti- #SARS-CoV-2 #antibody #assays across three doses of #BNT162b2 reveals insufficient #standardization of SARS-CoV-2 #serology, https://doi.org/10.1016/j.jcv.2022.105345
#comparison #sars #antibody #assays #BNT162b2 #standardization #serology
Six-Month Follow-up after a Fourth BNT162b2 Vaccine Dose
https://www.nejm.org/doi/full/10.1056/NEJMc2211283
This cohorts study, shows that the additional immunologic advantage of the fourth dose was much smaller than third dose. Three doses better than two.